We have analysed non-binding indicative offers
(NBIOs) for public companies during calendar years
2022 to 2024. In particular, we have done a deep dive on private
equity NBIOs.
The analysis provides insights on success rates of NBIOs and how
engagement might unfold. The conclusions from the data provide
valuable insights for private equity bidders.
Key Findings
1. First announced on agreed deal:
For all bidder types, the majority of NBIO approaches were not
announced until binding transaction documents were agreed. Only 25%
of these were private equity bidders, with other private equity
NBIOs being disclosed for various reasons before an agreed
deal.
2. Leak risk:
Only 12% of NBIOs were leaked, and 46% of these involved private
equity bidders, dispelling suggestions that Australia is a leaky
market and that private equity NBIOs are more likely to be
leaked.